Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 11, 2020 2:35:48 AM
A hot drug leads to a lot of interest in a stock, which is the key reason why Gilead's shares have generally been on the rise since the world became reacquainted or initially acquainted with remdesivir (formerly a treatment for Ebola). But I think that as an investment, the company has another very attractive factor that isn't getting quite so much attention -- or any at all.
Two medical professionals conferring in a busy hospital lobby.
IMAGE SOURCE: GETTY IMAGES.
Profit participation
That under-the-radar factor is Gilead's quarterly dividend, which is generous relative to the broader stock market's average dividend, and it's consistent and dependable to boot.
Since the company initiated the investor payout in 2015, it has risen steadily from $0.43 to the present level of $0.68 thanks to its annual raises. At the moment the dividend yield is 3.5%, which compares very favorably to the 2.1% average yield of all S&P 500 stocks (a group which, to be fair, includes numerous companies that don't pay dividends).
As with any dividend investment, though, we have to consider whether Gilead's payout is sustainable. After all, there's little point in buying a stock for its dividend if that payout will be reduced or eliminated -- which is not an unusual occurrence in an economy being rocked by the coronavirus pandemic.
Looking at the company's fundamentals in recent history, it usually lands in the black on an annual basis -- even following a big fall from its peak sales year of 2015, when it ruled the market for hepatitis treatments (though it has lately been recovering on both the top and bottom lines). From that year on, even with some scary drops in sales and net profit, its annual net margin never fell below 18%.
Wide margins typically mean strong cash flow, and that's the case for Gilead. The company's free cash flow isn't at 2015 levels, but it's still quite robust. For full-year 2019, that line item grew a healthy 11% year-over-year to over $8.3 billion. That year the company's total spending on its dividend was $3.2 billion, making the cash dividend payout ratio 39%. So the dividend is, at the very least, sustainable for now.
Assuming Gilead manages to enlarge that free cash flow figure again there's going to be plenty of room for more of those annual dividend raises. At least initially remdesivir won't be a money-spinner, as the company has said it will donate the doses it has on hand. A more promising avenue for growth is the company's HIV drug program, which is stuffed with no fewer than five blockbuster drugs. It also has two treatments in the pipeline, vesatolimod and elipovimab, that could cure HIV entirely.
Another potential blockbuster -- and maybe a multi-faceted one at that -- is immunology drug filgotinib, a rheumatoid arthritis treatment now under priority review by the FDA (it has also been submitted to regulators in Europe and Japan). The global market for rheumatoid arthritis is estimated in the tens of billions of dollars. On top of that, filgotinib is being evaluated for other indications such as ulcerative colitis and Crohn's Disease.
Power and potential
Of course, Gilead isn't the only game in this town; there are other established, cash-rich pharmaceutical companies that pay reliable dividends.
Abbott Laboratories (NYSE:ABT) has been increasing its own payout for decades, to the point where it's a Dividend Aristocrat. Its 2013 spinoff, AbbVie (NYSE:ABBV) inherited a place in that celebrated group of stocks and has kept it by raising the distribution on the regular (it's also still the big rheumatoid arthritis player with its Humira). Gilead's 3.5% yield is close to the midpoint of Abbott Labs' 1.6% and AbbVie's 5.5%.
But in my opinion, Gilead has explosive potential immediately in front of it, more so than Abbott Labs, AbbVie, or numerous other dividend payers in Big Pharmaville. Remdesivir aside, Gilead already has a strong portfolio and an excellent pipeline. Meanwhile, the company's solid cash-generating tendencies, its ability to grow, and its high profitability make it a fine stock for income investors.
Recent GILD News
- EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIH • PR Newswire (Canada) • 06/26/2024 02:45:00 PM
- Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains • IH Market News • 06/21/2024 12:00:38 PM
- Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention • Business Wire • 06/20/2024 12:51:00 PM
- Goldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and More • IH Market News • 06/17/2024 10:49:12 AM
- New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment • Business Wire • 06/14/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:23:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:20:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:18:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:15:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 11:12:00 PM
- Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA • Business Wire • 06/06/2024 08:30:00 AM
- Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis • Business Wire • 06/05/2024 06:00:00 AM
- Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia • Business Wire • 06/03/2024 02:00:00 PM
- Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma • Business Wire • 06/03/2024 01:00:00 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer • Business Wire • 06/02/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers • Business Wire • 06/01/2024 12:00:00 PM
- EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 • Business Wire • 05/31/2024 12:07:00 PM
- Gilead Provides Update on Phase 3 TROPiCS-04 Study • Business Wire • 05/30/2024 08:45:00 PM
- Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 • Business Wire • 05/22/2024 12:30:00 PM
- Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis • Business Wire • 05/18/2024 12:30:00 PM
- Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy • Business Wire • 05/14/2024 02:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:57:24 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM